Management of advanced-phase chronic myeloid leukemia.
The management of chronic myeloid leukemia (CML) in accelerated or blast phase (advanced phase) remains a significant challenge despite the introduction of very effective tyrosine kinase inhibitors (TKIs). The biology of advanced-phase CML is complex and engages several pathways that are not optimally targeted by TKIs. Allogeneic stem cell transplantation remains the only potentially curative therapy, but the effectiveness of this conventional approach is limited. New strategies are required to improve the outlook for these patients.
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Road NE C5010, Atlanta, GA, 30322, USA, zdefilipp@emory.edu.
Zachariah
Z
DeFilipp
Hanna Jean
HJ
Khoury
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001752:Blast Crisis / Q000628:therapy; D060830:Consolidation Chemotherapy / Q000379:methods; D019468:Disease Management; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015466:Leukemia, Myeloid, Chronic-Phase / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors